Effect of Oligopin Administration on Ovarian Morphology in Women with Polycystic Ovarian Syndrome (PCOS)

被引:1
作者
Sajjadi-Jazi, Sayed Mahmoud [1 ]
Sanginabadi, Milad [2 ]
Moradi, Behnaz [3 ]
Taheri, Amir Pejman Hashemi [2 ]
Amouei, Mehrnam [2 ]
Qorbani, Mostafa [4 ,5 ]
Hosseini, Saeed [6 ]
Gity, Masoumeh [7 ]
Mohajeri-Tehrani, Mohammad Reza [1 ]
Taheri, Seyed Vahid [8 ]
Mansour, Asieh [1 ]
机构
[1] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Endocrinol & Metab Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Shariati Hosp, Radiol Dept, Tehran, Iran
[3] Univ Tehran Med Sci, Dept Radiol, Tehran, Iran
[4] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran
[5] Univ Tehran Med Sci, Endocrinol & Metab Populat Sci Inst, Endocrinol & Metab Res Inst, Chron Dis Res Ctr, Tehran, Iran
[6] Tehran Med Sci Univ, Sch Nutr Sci & Dietet, Dept Clin Nutr, Int Campus, Tehran, Iran
[7] Univ Tehran Med Sci, Adv Diagnost & Intervent Radiol Res Ctr ADIR, Tehran, Iran
[8] Semnan Univ Med Sci, Student Res Comm, Semnan, Iran
关键词
INCREASED OXIDATIVE STRESS; INSULIN-RESISTANCE; DOUBLE-BLIND; ANTIOXIDANTS; RESVERATROL; ULTRASOUND; METFORMIN; STROMA; PROLIFERATION; APOPTOSIS;
D O I
10.1155/2024/6479885
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The effects of oligopin as an antioxidant on polycystic ovarian morphology (PCOM) have not yet been examined. Therefore, the objective of this study was to evaluate the oligopin supplementation on PCOM among patients with polycystic ovarian syndrome (PCOS). Methods. This randomized, placebo-controlled trial was carried out at Shariati Hospital, Arash Hospital, and Yas Hospital, Tehran, Iran, to determine the effect of oligopin (50 mg/d) or placebo in PCOS patients. The ultrasonographic ovarian morphology was assessed in women aged 18-40 years, before and after 3 months of intervention. Results. Among 45 randomized participants, 32 participants, of whom 17 were in the oligopin group and 15 were in the placebo group completed the trial. There was only one adverse event in the oligopin group. The mean (standard deviation) age of the patients was 30.47 (6.30) years and the median (interquartile range) BMI was 27.50 (23.42-33.55). Three months of oligopin therapy significantly decreased ovarian stromal area (p=0.01) and stromal/total area (p=0.003). However, no significant differences were observed in the ovarian volume, ovarian area, 2-9 mm antral follicle counts, or peripheral follicle distribution pattern at 3 months. Conclusion. Among participants with PCOS, the use of oligopin (50 mg) daily, as compared with a placebo, resulted in improvement of the stromal area and stromal/total area at the end of the 3 months of treatment. Further studies are, however, needed to evaluate the longer-term efficacy and safety. This trial is registered with IRCT20140406017139N3.
引用
收藏
页数:7
相关论文
共 50 条
[41]   Urinary Metabolites Reveal Hyperinsulinemia and Insulin Resistance in Polycystic Ovarian Syndrome (PCOS) [J].
Fulghesu, Anna Maria ;
Piras, Cristina ;
Dessi, Angelica ;
Succu, Claudia ;
Atzori, Luigi ;
Pintus, Roberta ;
Gentile, Cecilia ;
Angioni, Stefano ;
Fanos, Vassilios .
METABOLITES, 2021, 11 (07)
[42]   Systemic and ovarian inflammation in women with polycystic ovary syndrome [J].
Zhai, Yi ;
Pang, Yanli .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2022, 151
[43]   Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study [J].
Rencber, Selenay Furat ;
Ozbek, Sema Kurnaz ;
Eraldemir, Ceyla ;
Sezer, Zehra ;
Kum, Tugba ;
Ceylan, Sureyya ;
Guzel, Elif .
JOURNAL OF OVARIAN RESEARCH, 2018, 11
[44]   COMPARISON OF METFORMIN EFFECTIVENESS AMONG OBESE AND NON-OBESE WOMEN DIAGNOSED WITH PCOS (POLYCYSTIC OVARIAN SYNDROME) [J].
Butt, Muhammad Nadeem ;
Hussain, Sabir ;
Saaqib, Yasaan .
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (02) :2816-2820
[45]   Polycystic ovarian syndrome and pregnancy outcome [J].
Iavazzo, C. ;
Vitoratos, N. .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2010, 282 (03) :235-239
[46]   In Vitro Fertilization for Polycystic Ovarian Syndrome [J].
Zolton, Jessica R. ;
Torrealday, Saioa .
CLINICAL OBSTETRICS AND GYNECOLOGY, 2021, 64 (01) :39-47
[47]   Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study [J].
Sara Pittenger Reid ;
Chia-Ning Kao ;
Lauri Pasch ;
Kanade Shinkai ;
Marcelle I. Cedars ;
Heather G. Huddleston .
Fertility Research and Practice, 3 (1)
[48]   Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus [J].
Miyoshi, Arina ;
Nagai, So ;
Takeda, Masamitsu ;
Kondo, Takuma ;
Nomoto, Hiroshi ;
Kameda, Hiraku ;
Hirai, Amiko ;
Cho, Kyuyong ;
Kimachi, Kimihiko ;
Shimizu, Chikara ;
Atsumi, Tatsuya ;
Miyoshi, Hideaki .
JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (03) :326-329
[49]   Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis [J].
Haqq, Liza ;
McFarlane, James ;
Dieberg, Gudrun ;
Smart, Neil .
ENDOCRINE CONNECTIONS, 2014, 3 (01) :36-46
[50]   Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes [J].
Cela, Vito ;
Obino, Maria Elena Rosa ;
Alberga, Ylenia ;
Pinelli, Sara ;
Sergiampietri, Claudia ;
Casarosa, Elena ;
Simi, Giovanna ;
Papini, Francesca ;
Artini, Paolo Giovanni .
GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (06) :518-523